drugset
drugset / Trial / NCT05900765

A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma

NCT05900765 ↗

Phase 2 Unknown 54 enrolled Sun Yat-sen University Guangzhou Gloria Biosciences Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label single-arm phase II study to evaluate the efficacy and safety of Zimberelimab (GLS-010) combined with AVD for newly diagnosed early-stage Hodgkin's lymphoma under the guidance of PET/CT.

Timeline

Start
2023-06-14
Primary completion
2025-06-30
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dacarbazine Small molecule 0.375 mg/m2 Intravenous
Subject Doxorubicin Other / unclassified 25 mg/m2 Intravenous
Subject Vincristine Small molecule 3 mg/m2 Intravenous
Subject Zimberelimab Monoclonal antibody 240 mg —

Indications

classic Hodgkin lymphoma